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S216 Poster Session Idifferences were found between children and adults inTRM, relapse,
DFS or survival.
Conclusion:Our results suggest that adults and children have sim-
ilar outcomes after haplo-identical HCT. In vitro TCD in adults is
associated with worse outcomes in the cohort reported to
CIBMTR. Other prognostic factors such as advanced disease stage
in the CIBMTR cohort and Karnofsky score in the Chinese cohort
are consistent with those identified in studies of HLA-matched
donors.156
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) USING MYELOA-
BLATIVE AND NON-MYELOABLATIVE CONDITIONING FOR 38 PATIENTS
WITH ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nakano, N., Wake, A., Yamamoto, H., Shimazu, H., Ishiwata, K.,
Tuji, M., Mori-Asano, Y., Uchida, N., Yoneyama, A., Makino, S.,
Taniguchi, S. Toranomon Hospital, Tokyo, Japan
Aims: The aims of this study are to identify the clinical characteris-
tics and outcomes after uCBT for adult ALL patients.
Patients and Methods: There were 38 ALL patients (22 male, 16
female) who have undergone uCBT between February 2003 and Jan-
uary 2009 consecutively in our institute.We retrospectively analyzed
patients’ clinical characteristics, overall survival (OS), event-free sur-
vival (EFS), leukemia-free survival (LFS) after transplantation, and
these related factors.
Results:Median age was 51.5 yrs (18-68). Disease status at trans-
plantation were 8 patients in CR1, 10 advanced CR and 20 non-
CR. Ph positive patients were 14 and negative 24. Myeloablative
conditioning (MAC) regimens were used in 11 patients (all
TBI12 Gy/CY60 mg/kg based and 3 patients used additional
drugs such as VP16 and cytarabine), and 27 reduced intensity
(RIC) (mainly Flu125-180 mg/m2/Mel80-140 mg/m2/TBI4-8 Gy,
Flu180 mg/m2/BU6.4-8 mg/kg/TBI4-8 Gy based). Thirty patients
obtained engraftment. Median time to engraftment was 20.5 days
(11-56) after transplantation. Twenty-six patients died (11 disease
progression, 8 pneumonia, 3 sepsis, 2 diffuse alveolar hemorrhage,
1 acute GVHD and 1 MOF) and 18 relapsed after transplantation.
Twenty-seven patients had pre-engraftment immune reaction
(PIR), and 22 acute GVHD. Cumulative incidence of non-relapse
mortality (NRM) at day 100 after transplantation was 21.7%.
Two-year OS, EFS and LFS for all patients were 41.5%, 32.9%
and 33.9% respectively. Two-year OS of patients status in CR1,
advanced CR and non-CR at the transplantation were 50%,
50% and 17.1% respectively. Also 2-year OS, EFS of patients
with MAC and RIC were 39.8% vs 42.3% and 36.4% vs 33.8%
respectively. In univariate analysis, significant positive factors con-
tribute to OS, EFS, LFS were PIR. Use of additional drugs in
TBI/CY group showed significantly negative contribution to OS
and EFS.
Conclusions:We conclude that uCBT was feasible treatment for
the adult patients with ALL. Our results suggested no significant
differences between MAC regimen and RIC in uCBT for adult
ALL.157
MOTHER-BABY PARAMETERS IMPACT ON TNC AND CD34 + COUNTS IN
UMBILICAL CORD BLOOD BANKING
Villanueva, C., Pando, J., Saenz, P., Rios, H., Marquez, M., Honda, I.,
Aranda, I., Perez, I., Vidal, G., Huamani, J., Obregon-Zegarra, E.H.,
Carrasco, P., Vidurrizaga, M., Castillo-Aguirre, J., Carrasco-
Yalan, A.A. Criocord, Lima, Peru
Introduction: Umbilical cord blood (UCB) has become an eas-
ily, available and viable source of hematopoeitic SC for trans-
plant. The main limitation factor for its wide use is cell dose.
Previous studies had showed that certain physiological parame-
ters pertaining to the baby or the mother impact in the UCB
cell yields.Objectives: The aim of our study was to compare five physiological
parameters: mothers age [MA], gestational age at delivery [GA], gen-
der [G], birth weight [BW] and type of delivery [TD], comparing
with TNC and CD34 + cells recovery. We also evaluated the impact
of time from collection to processing (TCP) on CD45+ cells
viability.
Results: From May 2004 to Jun 2009, a total of 4262 UCB collec-
tions were performed. 77.87% were collected after cesarean; median
TCP was 30 hours 58 minutes. The mean CBU volume and TNC
count were 81.8 ml and 8.63  108 respectively. The colected vol-
ume was greater in cesarean delivery than vaginal delivery
(F5 30.82, p\0.001). TNC counts collected were directly corre-
lated with GA: in preterm delivery (\37sem) was 7.13108 and in
term delivery ($37sem) was 9.93108 and with BW (F5 325,
p\0.001) while the MA had inverse correlation (F5 8.05,
p5 0.005); regarding TD there was a significant mayor TNC count
in the vaginal vs. cesarean group (10.49108 vs. 9.22108,
F5 48.207, p\0.001); while it was a trend for major TNC count
in females vs. males babies (9.82108 vs. 9.13108, p5 0.059).
CD34+ cells count was directly correlated with BW (F5 70.1,
p\0.001). The strongest correlation was with GA (in preterm:
61.99 CD34+/ul and in term delivery: 84.67 CD34+/ul,
F5 27.62 p5\0.001); Moreover, there was association between
CD34+ cells count with TD (vaginal: 87.88 CD34+/ul vs cesarean:
80.26 CD34+/ul, F5 5.327 p5 0.02). There was not association ei-
ther with G (females: 79.97 CD34+/ul vs males: 83.48 CD34+/ul,
F5 1.668 p5 0.197) neither MA (F5 1.82, p5 0.177). There was
a significant difference between CD34+ viability cells among CBU
with less than 48 hours or more of TCP (99.6% vs. 99.4%,
p5 0.019); this difference was stronger when the CD45+ viability
was evaluated (93.35% vs. 90.14%, p\0,001).
Conclusions: TNC and CD34 +UCB cells are influenced by vari-
ables related to the mother -baby. It looks like on time female babies
with good weight, born to a younger mother and from a vaginal de-
livery reach highest TNCcount. CD34+ cells count was directly cor-
related with BW and CD34+ viability is mainly influenced by the
TCP.158
EFFECTS OF OBSTETRIC FACTORS ON WEIGHTS AND CELL COUNTS OF
CORD BLOOD UNITS
Platz, A.1, Schmidt, A.H.1,2, Aurich, A.-C.1, Solloch, U.V.2, Rutt, C.2,
Ehninger, G.3 1DKMS Lifeline Cord Blood Bank, Dresden, Germany;
2DKMS German Bone Marrow Donor Center, Tuebingen, Germany;
3University Hospital Carl Gustav Carus, Dresden, Germany
High cord blood unit (CBU) cell counts influence the outcome of
cord blood transplantation positively. Therefore, the identification
of obstetric factors that determine CBU cell counts is relevant for
cord blood bank operations.
We quantified weights and white blood cells per volume (WBC,
109/l) and per CBU (TNC, 108) of 206 consecutive CBUs with min-
imum weight 50 g that were sent to DKMS Lifeline Cord Blood
Bank from April to June 2009. The effect of 6 obstetric factors
(baby’s gender and birthweight,mother’s age at delivery and number
of previous pregnancies, gestational age, and birth route) on these
quantities was analyzed.
In univariate analysis, the following effects were significant (t tests,
p\0.05): High birth weight (.3500 g) and gestational age (.40
weeks) were associated with increased WBC (12.1 versus 10.5 and
12.4 versus 10.7, respectively) and TNC (11.2 versus 9.2 and 11.3
versus 9.5, respectively), higher age of mother ($31 years) correlated
with higher CBU weight (80.8 g versus 74.5 g), and vaginal delivery
was associated with higher WBC (12.8 versus 9.0) and TNC (11.3
versus 8.5) and lower CBU weight (75.3 g versus 81.7 g). Besides,
there was a trend to higher CBUweight in male babies (79.9 g versus
74.6 g) but differences were not significant (p5 0.06).
In multiple linear regression analysis, birth weight and birth route
were the only factors that significantly influenced CBU weight,
WBC, or TNC (p\0.05). High birth weight was associated with
high CBU weight (b5 0.22), high WBC (b5 0.20), and high
TNC (b5 0.26). Vaginal delivery correlated with low CBU weight
(b5-0.18), high WBC (b5 0.43), and high TNC (b50.20). Beta
values indicate standardized regression coefficients.
Poster Session I S217In cord blood bank practice, the 6 obstetric factors given above
and CBU weight are generally known before the decision on further
processing is made. In the respective regression model with TNC as
dependent variable, the highest absolute b values were reached for
CBU weight (b5 0.70) and vaginal delivery (b5 0.33) followed by
the number of preceding pregnancies (b5-0.13). These factors
were also significant at p5 0.05.
The presented data can be applied to optimize cord blood bank
operations. As one result one could, for example, establish different
CBUminimumweights for further processing subject to birth route:
since CBUs from vaginal deliveries have higherWBC counts, the re-
spective minimum weight could be lower than that of CBUs from
sectios.159
DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION ACHIEVES UNI-
VERSAL ENGRAFTMENT BUT IS ASSOCIATED WITH CONSIDERABLE
TRANSPLANT-RELATED MORTALITY
Baltadakis, I., Karakasis, D., Manaka, A., Panitsas, F., Poulopoulou, Z.,
Delistrati, V., Bika, E., Garofalaki, M., Papageorgiou, M.,
Vasileiou, S., Gigantes, S., Apostolidis, J., Harhalakis, N.,
Nikiforakis, E. Evangelismos Hospital, Athens, Greece
The applicability of umbilical cord blood transplantation (UCBT)
is limited by inadequate cell dose especially for adult patients. Infu-
sion of 2 partially HLA-matched units has been shown to facilitate
engraftment, and allows for transplantation of patients for whom
a single unit of sufficient cell dose is not available. However, double
UCBT is associated with an increased risk of acute graft-versus-host
disease (aGVHD), which may impair the outcomes. From 8/2006 to
7/2009, 21 patients (female:male5 10:11) with high-risk acute mye-
loid (AML, n5 16) or lymphoblastic (ALL, n5 5) leukemia received
double UCBT in our center. The patients had a median age of 36
years (range: 16-60), and a median weight of 75 kg (range: 53-105).
The median time from diagnosis to UCBT was 10 months (range:
3-91). The disease phase at transplant was 1st complete remission
(CR1) in 10 patients, CR2 in 5, and $CR3 or resistant relapse in
6. The conditioning regimen was myeloablative in 16 (TBI-based:
7, busulfan-based: 9), and reduced-intensity in 5 patients. ATG
was administered during conditioning only in 1 patient. Cyclospor-
ine plus mycophenolate mofetil was used for aGVHD prophylaxis.
The majority of UCB units (34/42) were 4/6 antigen matched to re-
cipient at HLA-A, -B, and -DRB1. The median total doses of nucle-
ated andCD34+ cells at infusionwere 4.3 10^7/kg (range: 2.65-5.4
 10^7/kg) and 1.33  10^5/kg (range: 0.6-3.1  10^5/kg), respec-
tively. Neutrophil recovery was achieved in all but 1 patient at a me-
dian of 19 days [cumulative incidence (CI) by day 52, 95%]. The CI
of platelet recovery (.50,000/uL) was 62% by day 270, and occurred
at a median of 83 days (range: 32-193). Eighteen patients (CI, 85%)
developed aGVHD (grade II-IV: 18, III-IV: 5). Three of 12 evalu-
able patients, who survived for more than 100 days, developed
chronic GVHD (CI, 14%). Treatment-related mortality (TRM)
was 38% at day 100 and 52% at 1 year. Causes of TRM were infec-
tion (n5 6), GVHD (n5 3), and transplant-associated microangi-
opathy (n5 2). Disease relapse occurred in 5 patients (CI, 28.5%
at 1 year). The 2-year disease-free and overall survival is 24% and
28%, respectively. Five patients are alive and in CR, 10-38 months
after UCBT. In conclusion, double UCBT results in an excellent
rate of engraftment in adult recipients. However, further improve-
ments should focus on the reduction of early TRM, which is signif-
icantly high and might be attributed to the increased incidence of
aGVHD.160
FLUDARABINE, CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN
(ATG) AS CONDITIONING REGIMEN IN MATCHED RELATED AND UNRE-
LATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR SEVERE
APLASTIC ANEMIA (SAA): THE M.D. ANDERSON CANCER CENTER TEN-
YEAR EXPERIENCE
Anderlini, P., Acholonu, S., Okoroji, G., Popat, U., Giralt, S.A.,
Shpall, E.J., Qazilbash, M., de Lima, M., Worth, L., Champlin, R.E.
The University of Texas M.D. Anderson Cancer Center, Houston, TXBackground: Total body irradiation (TBI) is often employed in
matched unrelated donor (MUD) allogeneic stem cell transplanta-
tion (allo-SCT) in SAA. However, even at low doses, TBI can cause
serious short- and long-term toxicities. In matched related donors
(MRD), outcome in SAA patients$ 40 years with high-dose cyclo-
phosphamide (CY)6ATG is poor due to graft rejection, GVHD
and organ failure. Aim: To explore feasibility of a fludarabine
(FLU)–based, high-dose ATG, TBI-free regimen in MUD (all
ages) and MRD (recipient. 40 years) allo-SCT.
Methods:Over a 10-year period (1999-2009), twenty SAA patients
underwent allo-SCT with a FLU-CY-ATG regimen from a MRD
(n5 7, all age$ 40) or a MUD (n5 13, any age). Median age was
34 years (range 1-59). Seven pts (33%) were$ 50 years old. Bone
marrow was used as SC source in all but four patients. Once the
regimen was standardized, it included (n5 13) FLU (30 mg/m
sq  4 days) intravenously (IV), CY (300 mg/m sq IV  4 days),
and thymoglobulin (THY, 3.75 mg/kg IV  3-4 days). Before
that, in seven patients doses were FLU 20-50 mg/m sq IV  4
days; CY 40-60 mg/kg IV  2-4 days; ATG IV 20-30 mg/kg
(horse product) or 3 mg/kg (THY) x 2-4 days. Median time
from diagnosis to allo-SCT was 12 months (2-244). Eleven pa-
tients (55%) were transplanted off study (active infection, poor or-
gan function, etc).
Results: Seventeen out of 19 evaluable patients engrafted (90%).
There were two secondary graft failures (10%). Median time to neu-
trophil recovery (i.e. absolute neutrophil count$ 500/mL) was 15
days (range 8-30). Chimerism studies indicated $90% donor-de-
rived engraftment in 16/19 evaluable patients (75%) and thirteen pa-
tients were 100% donor. Four out of 20 evaluable patients (20%)
developed acute grade II-IV GVHD, and 6/16 evaluable patients
(37%) developed chronic GVHD. Thirteen patients (62%) are alive
(including eight out of the last nine treated) with a median follow-up
of 30 months (3-112). Seven patients expired (graft rejection n5 1,
infection n5 2, GVHDn5 1, organ failure n5 1, EBV lymphopro-
liferative disorder/LPD n5 2). There was one early death (death\
day +30) and no known late graft failures.
Conclusion: Fludarabine-based, TBI-free for MRD and MUD
allo-SCT is feasible in this high-risk group (older age, active infec-
tion, poor organ function, etc), with high engraftment rates and
low early mortality. Presumably due to high-dose ATG, GVHD-
related incidence and mortality were low, although EBV LPD
was a drawback.161
MULTIPLE UNIT UMBILICAL CORD BLOOD TRANSPLANTATION (MU
UCBT) WITH TOTAL BODY IRRADIATION, ETOPOSIDE AND ANTITHYMO-
CYTE GLOBULIN FOR ADULT HEMATOLOGIC MALIGNANCY PATIENTS
Sobecks, R., Copelan, E., Kalaycio,M., Askar,M., Rybicki, L., Serafino, S.,
Serafin,M., Macklis, R., Dean, R., Pohlman, B., Andresen, S., Bolwell, B.
Cleveland Clinic, OH
MU UCBT is an alternative donor transplant approach for adult
hematologic malignancy (HM) pts. TBI and VP16 is an effective
conditioning regimen, but its utility in MU UCBT is not well
known. From 10/03-2/09 we enrolled 16 adult HM pts on a trial
with this regimen prior to MU-UCBT. Eligibility included lack of
an HLAmatched related or unrelated donor. Pts had to have at least
a 4/6HLAmatchedUCB unit with at least 0.5 107 nucleated cells/
kg and a 2ndUCB unit with at least a 4/6HLAmatch to the 1st UCB
unit. The minimum required cryopreserved TNC dose for both
units was 1  107/kg or an infused CD34+ cell dose of 1.5  105/
kg. Pts received TBI 1,320 cGy (days -7 to -4), VP16 60 mg/kg
(day -3) and ATG 30 mg/kg (days -3 to +1). GVHD prophylaxis: ta-
crolimus and mycophenolate. Median age was 47 yrs (range, 18-60)
and diagnoses were 8 AML, 3 CML, 2MDS, 1 ALL, 1 CLL 1NHL.
Median time from diagnosis to UCBT was 8 mos. The 1st UCB unit
infused (UCB1) included five 4/6, ten 5/6 and one 6/6 HLAmatches
with the recipient, and for the 2nd UCB unit (UCB2) with recipient
there were one 3/6, five 4/6, and ten 5/6 matches. Median thawed
TNC doses infused for UCB1 and UCB2 were 1.6  107/kg and
1.2  107/kg, respectively; thawed CD34+ cell doses were 0.6 
105/kg for both units.12 were evaluable for engraftment; 3 others
